Lifeward (Nasdaq: LFWD) bets on oral insulin platform to escape medical device treadmill

Lifeward Ltd. (Nasdaq: LFWD), a medical technology company operating across wearable robotic rehabilitation and now oral drug delivery, reported Q4 and full-year 2025 financial results on March 18, 2026, alongside confirmation that shareholders have approved its landmark strategic investment agreement with Oramed Pharmaceuticals. Under the transaction, Lifeward acquires Oramed’s clinical-stage Protein Oral Delivery (POD) technology platform in exchange for granting Oramed up to 49.99 percent equity ownership, plus access to up to $47 million in funding commitments designed to extend Lifeward’s cash runway toward cash flow positive. The announcement reframes Lifeward from a single-category rehabilitation device maker into a hybrid biomedical innovation vehicle, a pivot that carries both meaningful opportunity and substantial execution risk.

How has LFWD stock performed leading into the Oramed deal close and earnings release?

Lifeward shares have been under sustained pressure over the past twelve months, consistent with the company’s recurring losses and persistently thin cash position. The stock entered 2026 at pre-split levels that necessitated a 1-for-12 reverse share split, which was executed on February 24, 2026, to satisfy Nasdaq minimum bid requirements. Post-split, LFWD was trading in the range of $4.50 to $6.00 heading into today’s earnings release, against a 52-week adjusted high of approximately $6.00. The sole analyst covering the stock at the time carried a Strong Buy rating with a price target of $6.50. That a small-cap MedTech company with $2.2 million in unrestricted cash and a $20 million annual burn rate commands any buy-side interest at all reflects the speculative value embedded in the Oramed transaction rather than confidence in the existing revenue trajectory.

What do Lifeward’s full year 2025 revenues reveal about the health of its core device business?

Full-year 2025 revenue of $22.0 million represented a 14 percent decline from $25.7 million in 2024, and the deceleration was broad-based. AlterG product and service revenue, the largest single contributor at $12.9 million, fell 18 percent, primarily because a key international distributor front-loaded purchases in 2024 and is expected to resume a normalized order cadence in 2026. That is a timing-driven explanation management has offered for multiple quarters, and investors are entitled to scrutinize it carefully until the rebound actually materializes. ReWalk Personal Exoskeleton revenue slipped 3 percent to $8.5 million despite a meaningful reimbursement milestone late in the year, suggesting that coverage expansion is necessary but not sufficient to drive near-term unit growth. The steepest product-level decline came from MyoCycle FES bikes, where revenue halved to $0.6 million as Lifeward deliberately exited an exclusive distribution arrangement that no longer aligned with its proprietary portfolio focus. That strategic retreat made sense on paper but left an incremental revenue hole during a year the company could not afford one.

In Q4 specifically, revenue fell 33 percent year on year to $5.1 million, with AlterG down 43 percent due to the same distributor timing dynamic. ReWalk Personal was the only product line showing meaningful growth, up 20 percent to $1.8 million driven by higher reimbursed unit sales. The Q4 composition tells two different stories simultaneously: an underlying rehabilitation robotics business that is slowly gaining reimbursement traction, and a broader revenue base still working through structural and channel transitions.

Why did Lifeward’s adjusted gross margin compress even as GAAP gross margin improved in 2025?

Lifeward’s GAAP gross margin expanded to 38.2 percent in 2025 from 32.0 percent in 2024, a figure that looks encouraging at face value. However, the improvement is largely attributable to the absence of $3.3 million in intangible asset amortization that had been absorbed into 2024 cost of revenues. On a non-GAAP basis, adjusted gross margin actually declined to 40.9 percent from 42.7 percent, reflecting the underlying pressure of lower sales volumes spreading fixed manufacturing costs across a smaller revenue base, compounded by higher tariffs and freight expenses. In Q4 alone, non-GAAP gross margin collapsed to 32.6 percent from 45.5 percent a year earlier, driven by the same fixed-cost deleverage mechanism. This dynamic is important context for investors evaluating the Oramed deal: even with improved operational discipline at the expense line, the core device business is structurally exposed to margin contraction in any quarter where volume disappoints.

How much did Lifeward reduce operating expenses in 2025 and what drove the improvement?

Total GAAP operating expenses fell 25 percent to $28.1 million in 2025, primarily because the 2024 base included a $9.8 million impairment charge on acquired intangibles, compared to a $2.8 million goodwill impairment charge recognized in 2025. Strip those non-recurring items out, and non-GAAP operating expenses declined a more modest 12 percent, to $24.1 million from $27.5 million. The real underlying improvement came from R&D discipline following the completion of major development programs, and from efficiency gains in the commercial infrastructure. Sales and marketing expense of $13.9 million remained elevated at 63 percent of revenue, an uncomfortable ratio that reflects a commercial model still in transition. General and administrative costs rose notably to $8.2 million from $5.2 million, partly due to Oramed transaction costs. Lifeward management expects the positive trend in sales and marketing efficiency to continue into 2026 as it reinvests in R&D to bring new products forward.

How critical is the Oramed financing to Lifeward’s near-term survival as an operating company?

Lifeward entered 2026 with $2.2 million in unrestricted cash and cash equivalents, against a full-year 2025 operating cash outflow of $16.8 million. The arithmetic is straightforward: without external funding, the company had weeks, not quarters, of independent runway. The Oramed transaction changes this materially. On closing, Lifeward expects to draw on a secured convertible note with Oramed and an additional investor, and the broader funding framework provides access to up to $47 million across equity, convertible notes, milestone payments, and warrants. Oramed will also fund and manage the clinical development associated with the POD technology platform, capping Lifeward’s direct cash obligations in that vertical while preserving its economic upside. The going concern question, which had been a genuine overhang through 2025, is addressed, at least provisionally, by this structure. Execution risk has not disappeared, but the near-term liquidity cliff has been substantially reduced.

What does acquiring Oramed’s POD oral drug delivery platform actually mean for Lifeward’s long-term strategy?

The Protein Oral Delivery platform is the intellectual cornerstone of the Oramed partnership. At its core, the technology is designed to protect protein-based drugs from degradation in the gastrointestinal tract, enabling oral delivery of biologics that would otherwise require injection. The lead drug candidate, ORMD-0801, targets oral insulin delivery for type 2 diabetes and has generated Phase 2 and Phase 3 data. Oramed plans to initiate a 60-patient U.S.-based clinical trial, and importantly, Oramed will fund and manage that development independently, leaving Lifeward as a platform owner rather than a clinical operator for this asset.

The strategic logic of this arrangement is that Lifeward gains a seat at the table in one of the largest addressable markets in pharmaceutical history, type 2 diabetes drug delivery, without absorbing the capital intensity typically required to get there. For Oramed, ceding up to 49.99 percent of Lifeward in exchange for placing its technology inside a commercialization-oriented company provides a route to broader clinical and commercial infrastructure than a pure pharma company might independently develop. The tension in this logic is whether a company with $22 million in annual medical device revenue and a team historically focused on exoskeletons and anti-gravity treadmills can credibly add value to an oral biologic platform beyond hosting it on its balance sheet.

What is the strategic rationale for Lifeward’s acquisition of upper-body exoskeleton technology from Skelable?

Alongside the Oramed transaction, Lifeward moved quickly to demonstrate strategic momentum through a separate acquisition: powered upper-body exoskeleton technology and prototypes from Skelable for $480,000 in Lifeward equity and a nominal cash payment, with the Skelable engineering team joining Lifeward. The device is designed for post-stroke upper-limb rehabilitation. Management expects commercial readiness within approximately 18 to 24 months, subject to further development and regulatory approvals. The acquisition is designed to slot into the same distribution, reimbursement, and clinical infrastructure already supporting the ReWalk Personal Exoskeleton, creating incremental addressable market without requiring a parallel commercial build-out. The gross margin and unit economics profile is described as attractive, though no specific figures have been disclosed. At less than $500,000 in consideration, the deal is low-risk on absolute terms. The question is whether a company with the current operational bandwidth and cash constraints can execute two major strategic integrations simultaneously without either suffering.

How significant is Aetna, Humana, and UnitedHealthcare coverage for ReWalk Personal and what does it mean for revenue growth?

The addition of Aetna Medicare Advantage coverage for the ReWalk Personal Exoskeleton, joining Humana and UnitedHealthcare, represents a genuine commercial milestone. Together, these three payers cover approximately 16 million Medicare Advantage beneficiaries in the United States. For a wearable medical device targeting spinal cord injury patients, reimbursement access is the primary demand-side constraint: without insurance coverage, the product is effectively unaffordable for most patients. The expansion to three major Medicare Advantage plans materially raises the ceiling on potential reimbursed unit volume. However, coverage authorization and actual utilization are not the same variable. Channel partnerships that Lifeward transitioned to during the second half of 2025 still require time to scale, and the Q4 revenue numbers suggest those partnerships have not yet generated meaningful commercial output. The reimbursement runway is significantly improved; converting that runway into revenue remains the execution challenge for 2026.

What are the key execution risks facing Lifeward as it attempts a dual-track transformation in 2026?

Lifeward is simultaneously managing a commercial channel rebuild in its core device business, integrating two technology acquisitions, absorbing a 49.99 percent equity dilution from a strategic partner, and beginning operations in an entirely new therapeutic category. Each of these individually would be a significant management distraction; pursuing all four in parallel at a company with roughly $22 million in annual revenue and negative cash flow requires a level of execution precision that small-cap MedTech companies rarely sustain without operational missteps.

The AlterG revenue timing argument, the MyoCycle wind-down, and the ongoing channel transition costs all need to resolve favorably in 2026 for the core business to contribute meaningfully to the path toward cash flow positive. If AlterG distributor orders do not resume, or if the hybrid commercial model takes longer to scale than expected, Lifeward will find itself dependent on Oramed funding drawdowns rather than organic revenue momentum. The oral insulin clinical trial outcome, which Oramed controls, will determine whether the POD platform generates demonstrable value within Lifeward’s ownership structure or remains a long-dated option. The Shirley Ryan AbilityLab research collaboration, the international distribution expansion into Mexico, Thailand, and the United Arab Emirates, and the Nasdaq compliance restoration are all positive signals, but they do not directly address the near-term revenue or cash generation challenge.

Key takeaways: What Lifeward’s Q4 2025 results and Oramed deal mean for investors and the rehabilitation technology industry

• Lifeward ended 2025 with $2.2 million in unrestricted cash against a $16.8 million annual operating outflow; the Oramed deal is not optional for near-term survival, it is a structural necessity.
• The Oramed POD platform gives Lifeward exposure to oral insulin and oral biologic delivery, a multi-billion-dollar market, without direct clinical funding obligations, though the commercial benefit is long-dated.
• Full-year 2025 revenue of $22.0 million was down 14 percent, with AlterG timing distortions masking underlying demand trends that need to improve materially for the revenue trajectory to reverse.
• GAAP gross margin improvement to 38.2 percent is primarily a base-effect comparison artifact; non-GAAP adjusted gross margin actually declined to 40.9 percent, reflecting structural fixed-cost pressure.
• ReWalk Personal Exoskeleton reimbursement coverage now spans Aetna, Humana, and UnitedHealthcare, reaching approximately 16 million covered Medicare Advantage lives, a meaningful long-term demand enabler.
• The Skelable upper-body exoskeleton acquisition, at under $500,000 in equity consideration, is capital-efficient but adds integration complexity at a company already executing two major strategic pivots.
• Lifeward’s U.S. commercial hybrid model is not yet generating measurable revenue uplift, and the 2026 test will be whether channel partnerships scale before Oramed funding becomes the primary liquidity source.
• Operating expenses are improving with non-GAAP opex down 12 percent, but sales and marketing remains at 63 percent of revenue, an unsustainable ratio without a significant revenue step-up.
• The 1-for-12 reverse share split and subsequent Nasdaq compliance restoration remove a near-term delisting risk but do not change the fundamental operating economics of the business.
• Competitors in rehabilitation robotics, including Ekso Bionics and Cyberdyne, are watching closely; Lifeward’s reimbursement progress and the Oramed-funded clinical pipeline could differentiate its competitive position if execution is sustained.